公司资料
Biofrontera Inc 股价、新闻与催化剂
- 股票代码:
- BFRI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.35 USD (+3.85%)
收盘价
最后更新: 2026年8月17日
13.2M USD
市值
股价为何变动
As of Aug 17, 2026, BFRI closed up 3.85% at $1.35. No new same-company headline was identified in the current news window.
公司概览
Dermatology Photodynamic Therapy
Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines Ameluz, a topical photosensitizer, with the RhodoLED illumination system.
Actinic Keratosis Franchise
Ameluz is established in actinic keratosis and is being developed for broader treatment fields and additional body locations. The company is also pursuing superficial basal cell carcinoma and acne to expand the platform.
U.S. Commercial Infrastructure
Biofrontera operates a specialist dermatology sales organization and has restructured its economics with Biofrontera AG to retain a larger share of product value.
未来催化剂
- FDA action on the Ameluz supplemental application for superficial basal-cell carcinoma in late September 2026.
- Potential U.S. launch of Ameluz in superficial basal-cell carcinoma in the first quarter of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。